

BEFORE THE NATIONAL GREEN TRIBUNAL**WESTERN ZONE BENCH, PUNE**

(Under Section 16 read with Section 14 & 15

Of The National Green Tribunal Act 2010)

Original Application No. 31 of 2025**In the matter of:**

Rishan Sarode & 7 Ors

... Applicants

VERSUS

The Pune Municipal Corporation & 9 Ors

...Respondents**AFFIDAVIT INDICATING THE RISE OF GUILLAIN-BARRE
SYNDROME**

I, Rishan Sarode the Applicant No. 1 aged – Adult Occ – Student R/a- Flat no. 9, Varsha Apt, Gangote lane, opp Datta Mandir Kamla Nehru Park, Bhandarkar road, Pune 411004. on behalf of myself as well as on behalf of the Applicant Nos. 2 to 8 do hereby solemnly affirm on oath as under : -

1. That I am the Applicant in the above-mentioned matter and am fully conversant with the facts of the case.



That this Hon'ble Tribunal in last hearings, had observed that the spread of Guillain-Barre Syndrome appeared to be on the decline.

3. However, I wish to place on record that recent updates show a change in circumstances. I respectfully submit that there now exists a new significant cause for concern.
4. A recently published news article in Technology Networks dated 05/06/2025 cites a study which concluded that Guillain Barre Syndrome risk is linked to Covid-19 and certain other vaccines. This has been supported by the article titled "Guillain-Barre Syndrome in association with COVID-19 vaccination: a systematic review" published on which further draws a link between the two. **(The news article as well as the study are annexed herewith as Annexure-M)**
5. Furthermore, a news article in the Indian Express dated 10/06/2025 reports that the active COVID-19 case count in India stands at 6,815 as of 8:00 AM IST, with 324 fresh cases and 3 reported deaths in the last 24 hours alone. **(A copy of the said news article is annexed herewith as Annexure-N)**
6. Taken together, these reports give rise to a reasonable and evidence-backed apprehension of GBS cases emerging again as the aftermath of the rising Covid-19 infection.
7. In light of these developments, I request this Hon'ble Tribunal to consider that the earlier observed decline of in GBS cases may no longer reflect the present. Given the rising Covid-19 cases and their possible connection to GBS, constitutes a serious public health concern that deserves the Hon'ble Tribunal's urgent attention.

8. I am filing this Affidavit solely with the intention of assisting this Hon'ble Tribunal with updated information, so that any future directions may take into account the current status.

9. The facts stated herein are true and correct to my knowledge and belief.

Place- Pune

Dated- 16/06/2025

[Handwritten Signature]
Applicant

[Handwritten Signature]
Advocate for the Applicant




BEFORE ME

[Handwritten Signature]

**SHRUTI SUBHASH SANKPAL
ADVOCATE & NOTARY,
GOVERNMENT OF INDIA**


**Noted & Registered
at Serial No 1176/2025
Date 16 JUN 2025**

16 JUN 2025



Guillain-Barré Syndrome Risk Linked to COVID-19 and Certain Vaccines

News Published: June 5, 2025
[Original story from the University of Auckland](#)



A new international study analysing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain Covid-19 vaccines, and Guillain-Barré syndrome.

This research reinforces the importance of continuous vaccine safety monitoring and highlights key differences in risk associated with different vaccine types.

Guillain-Barré syndrome is a rare but serious neurological condition that can cause

progressive limb weakness and eventual paralysis, with an annual incidence of one to four cases per 100,000 people worldwide. It has been linked to various infections, including *Campylobacter jejuni*, Zika virus, influenza, and SARS-CoV-2.

The study used advanced epidemiological methods and healthcare data from 20 sites within the Global Vaccine Data Network (GVDN): seven sites from the African Covid-19 Vaccine Safety Surveillance (ACVaSS) system: Ethiopia, Ghana, Kenya, Malawi, Mali, Mozambique, and Nigeria; Argentina; New South Wales and Victoria in Australia; British Columbia and Ontario in Canada; Denmark; Finland; Indonesia; Republic of Korea; South Africa; and three Vaccine monitoring Collaboration for Europe (VAC4EU) sites: Catalonia and Valencia in Spain, and the United Kingdom.

"Our findings emphasise that vaccine safety is not static. It is continuously studied and evaluated." Associate Professor Helen Petousis-Harris Global Vaccine Data Network, University of Auckland

People infected with SARS-CoV-2 were around three times more likely to develop Guillain-Barré syndrome within six weeks of infection compared with other times, suggesting that infection with this virus increases the risk of Guillain-Barré syndrome.

An increased risk was also observed following adenoviral vector vaccines (AstraZeneca, Janssen/Johnson & Johnson), but not after mRNA vaccines (Pfizer-BioNTech, Moderna) or inactivated vaccines (Coronavac/Sinovac).

"If you are concerned about the risk of rare but serious side effects of vaccines such as Guillain-Barré syndrome, you should know that receiving an mRNA COVID-

19 vaccine does not appear to increase your risk, but infection with the virus does," said Dr Jeff Kwong, senior author for the study based at ICES and the University of Toronto in Canada.

"This study reinforces what we have known for some time – the potential health risks from Covid-19 disease are greater than the risks following Covid-19 vaccination, which plays an important role in protecting us from serious risks posed by infection.

"Understanding the relative risks of vaccination and infection is critical. This study reinforces that while certain vaccines may carry small risks, SARS-CoV-2 infection itself presents a much greater threat to neurological health," said Dr Sharifa Nasreen, an assistant professor at SUNY Downstate Health Sciences University, USA.

"Our findings emphasise that vaccine safety is not static – it is continuously studied and evaluated. The global research community remains committed to ensuring public confidence through ongoing safety monitoring and evidence-based guidance," said Associate Professor Helen Petousis-Harris, GVDN co-director, based at the University of Auckland.

GVDN collaborates with leading research institutions, policymakers, and vaccine organisations across six continents to create a comprehensive, evidence-based approach to vaccine safety and effectiveness. This large-scale study underscores the importance of vaccination as a tool for public health, not only in preventing severe disease but in reducing rare complications like Guillain-Barré syndrome.

Dr Steve Black, GVDN co-director, stated, "GVDN has long been committed to rigorous and transparent vaccine safety research. The size and diversity of this study population, attained through multinational collaboration, is a testament to

this. Our findings highlight the importance of continuous monitoring and real-world data to guide public-health decisions.”

Reference: Nasreen S, Jiang Y, Lu H, et al. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study. *Vaccine*. 2025;60:127291. doi: [10.1016/j.vaccine.2025.127291](https://doi.org/10.1016/j.vaccine.2025.127291)

This article has been republished from the following [materials](#). Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed [here](#).

**Technology
Networks**

©2025 Technology Networks, all rights reserved, Part of the LabX Media Group

Covid 19 India Cases Live Updates: 783 Covid

patients recover, active cases in Delhi shrink by 37

Six Covid-19-related deaths were reported -- one each in Delhi, Kerala, Jharkhand and Maharashtra, and two Karnataka.

-
-
-
-

By: Express Web Desk Updated: June 11, 2025 10:32 IST



As many as 783 patients were cured/discharged/migrated from across the country till this morning, as per the official website. (Express Archive)

As many as 783 patients were cured/discharged/migrated from across the country till this morning, as per the official website, as per the Ministry of Health and Family Welfare. The total number of active Covid-19 cases in India touched 6,815, as of 8 am on Tuesday, as the number of active cases increased by 324. Six new Covid-19-related deaths were reported — one each in Delhi, Kerala, Jharkhand and Maharashtra, and two Karnataka. **Major states affected:** Kerala continues to be the most affected state with active cases tally reaching 2,053 early Tuesday. 96

fresh cases of the virus were reported in the state in the last 24 hours. It is followed by Gujarat, West Bengal and Delhi according to the MoHFW data, with the Capital reporting a reduction in the number of active Covid-19 cases from 728 on Monday to 691 today.

What we know about the surge in cases: The current surge of Covid cases in India is driven by new Omicron sub-variants such as JN.1, NB.1.8.1, LF.7, and XFC. These are known to have shown increased transmissibility but mostly mild symptoms. The WHO currently classifies these as “Variants Under Monitoring” — not of concern yet, but requiring caution. Meanwhile, SARS-CoV-2, the virus responsible for Covid-19, has not disappeared, but it no longer behaves like an unpredictable emergency — rather, it has become part of a recurring cycle of illnesses, similar to the flu.